DermTech, Inc., a dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions, presented their recent work during the 2015 Annual Meeting of the American Academy of Dermatology in a study entitled “Melanoma gene expression in adhesive-tape sampled lesions is similar in primary tumors and patient derived xenografts.” (AAD 2015 #1848).
MRV Research
Navidea Biopharmaceuticals Announces Presentation of Lymphoseek® Data at Society of Surgical Oncology Meeting
Navidea Biopharmaceuticals, Inc., today announced that data from its Lymphoseek® (technetium Tc 99m tilmanocept) injection studies in melanoma, breast and oral cavity squamous cell cancers (SCC) will be presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Houston, TX, March 25-28, 2015.
UCLA Researchers Develop Effective Triple Combination Therapy for Melanoma
Researchers at the University of California, Los Angeles (UCLA) recently published in the journal Science Translational Medicine results of a groundbreaking effective triple combination therapy for advanced melanoma. The study is entitled “Improved anti tumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma.”
Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma
The development of agents targeting the PD-1 immune checkpoint in the treatment of patients with advanced melanoma is progressing rapidly, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials, according to Jason J. Luke, MD, FACP.